Skip to content
Review

Targeting KRAS-Mutant Lung Cancers.

Sep 2026 · The Journal of the National Comprehensive Cancer Network · pp. 1-8 · 0 citations · 63 references
Medicine

TL;DR

KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS-mutant NSCLC are comprehensively summarized.

Abstract

KRAS mutations are the most common oncogenic driver alterations in non-small cell lung cancer (NSCLC) and define biologically heterogeneous diseases shaped by mutation subtype, co-mutation patterns, and immune contexture. Recent advances in structural and chemical biology have transformed KRAS from an undruggable target into a rapidly expanding therapeutic vulnerability. The first allele-specific inhibitors, sotorasib and adagrasib, validated KRASG12C as a druggable dependency, changing the treatment paradigm for previously treated KRASG12C NSCLC, although primary, acquired, and adaptive resistance remain widespread. Next-generation inhibitors such as divarasib improve potency and tolerability but continue to face resistance through secondary KRAS alterations, bypass receptor tyrosine kinase (RTK) signaling, and adaptive MAPK reactivation. These challenges have spurred the development of KRAS(ON) inhibitors, dual ON/OFF inhibitors, and broader pan-KRAS and pan-RAS agents capable of targeting multiple oncogenic variants, including G12D, G12V, G12X, G13X, and Q61X. Early clinical results with tricomplex RAS(ON) inhibitors (eg, daraxonrasib) and G12D-selective agents (eg, zoldonrasib) demonstrate promising activity in subsets historically lacking targeted options. In parallel, rational combination strategies aimed at enhancing overall efficacy, such as RTK, SHP2/SOS1, or PD-1/PD-L1 blockade, together with emerging modalities including RAF-MEK clamps, adoptive cell therapies, and KRAS vaccines, are broadening the therapeutic landscape. This review comprehensively summarizes KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS-mutant NSCLC.

View source

Similar papers

Review Sep 2026

Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer

ABSTRACT Introduction Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in which activating KRAS mutations, present in more than 90% of tumors, constitute the principal oncogenic driver. Advances in structural biology have enabled the pharmacologic targeting of KRAS, a protein historically regarded as...

Joanna Kreidi, C. Hoyek, C. Eslinger et al. · 0 citations
Review Sep 2026

Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers

The rapid evolution of KRAS-targeted therapeutic agents represents a shift from allele-specific inhibition towards a strategy that is mutation/context-dependent, thereby creating further clinical translation opportunities and increased patient benefit.

Srijita Chatterjee, S. Arya, Nidhi Sharma et al. · 0 citations
Review Aug 2026

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms

KRAS-mutant NSCLC is transitioning from historically untargetable disease to a therapeutically actionable subset, and future progress hinges on resistance-directed combinations, biomarker-guided personalization, expansion to non-G12C mutants, and evaluation in earlier disease settings.

A. Kapoor, Bipinesh Sansar, Anuj Gupta et al. · 0 citations
Review Open access Sep 2026

Molecular landscape of KRAS G12C inhibitor resistance and rational combination strategies in cancer therapy

Background: Oncogenic alterations in KRAS are among the most frequent driver mutations in human cancers, particularly lung, colorectal, and pancreatic cancers. Mutant KRAS was historically considered an “undruggable” target because of its high affinity for guanosine triphosphate and guanosine diphosphate (GDP) and the...

V. Adhao, Sakshi N. Patil · 0 citations
Review Sep 2026

Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V

The development of MRTX1133, zoldonrasib, zoldonrasib (RMC-9805), VS-7375, RMC-5127, and daraxonrasib (RMC-6236) demonstrates that direct targeting of previously undruggable KRAS alleles is becoming clinically feasible, and anti-EGFR combination strategies particularly important in CRC.

T. Sagawa, Masahiro Hirakawa, H. Nagashima et al. · 1 citation
Review Oct 2026

Targeting RAS in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, and activating KRAS mutations occur in more than 90% of tumors. Direct RAS targeting has moved from proof of concept to randomized clinical benefit: in previously treated metastatic PDAC, daraxonrasib improved median overall survival, p...

F. Petrelli, L. Dottorini, A. Zaniboni · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.